Related Experiment Video
Updated: May 23, 2026
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
Epidermal growth factor vaccine in non-small-cell lung cancer
Gisela M Gonzalez Marinello1, Edgardo S Santos, Luis E Raez
1Division of Business and Development Center of Molecular Immunology, Havana, Cuba. gisela@cim.sld.cu
Abstract:
After many years of uncertainty regarding the role of immunotherapy in cancer, we finally have vaccines approved for the treatment of some malignancies (e.g., prostate cancer and melanoma). In non-small-cell lung cancer, several vaccines are being studied in randomized Phase III clinical trials due to their promising results seen in the clinic, such as BLP-25 and melanoma-associated antigen A3. Traditionally, non-small-cell lung cancer has not been considered a good target for immunotherapy due to lack of immunogenicity and the strong presence of regulatory T cells, which do not allow an adequate immune response in the host. EGF vaccination is a novel area of immunotherapy for this disease. Thus far, there has been success in generating immune and clinical responses with this vaccine in several clinical trials, and we will review in depth the efficacy and toxicity of this novel agent.
Insights
Immunotherapy vaccines are now approved for some cancers. For non-small-cell lung cancer, Epidermal Growth Factor (EGF) vaccination shows promise in clinical trials, generating immune and clinical responses.
Area of Science:
- Oncology
- Immunotherapy
- Vaccine Development
Background:
- Immunotherapy has shown recent success in treating malignancies like prostate cancer and melanoma.
- Non-small-cell lung cancer (NSCLC) has traditionally been challenging for immunotherapy due to low immunogenicity and immunosuppressive regulatory T cells.
- Existing NSCLC vaccine candidates, such as BLP-25 and MAGE-A3, are under investigation in Phase III trials.
Purpose of the Study:
- To review the efficacy and toxicity of Epidermal Growth Factor (EGF) vaccination as a novel immunotherapy for non-small-cell lung cancer.
- To explore the potential of EGF vaccination in overcoming the challenges associated with immunotherapy in NSCLC.
Main Methods:
- Review of clinical trial data focusing on EGF vaccination in non-small-cell lung cancer.
- Analysis of immune responses and clinical outcomes associated with EGF vaccination.
- Assessment of the safety profile and toxicity of EGF vaccination.
Main Results:
- EGF vaccination has demonstrated success in generating both immune and clinical responses in patients with non-small-cell lung cancer.
- Early clinical trials indicate a favorable profile for this novel therapeutic approach.
Conclusions:
- Epidermal Growth Factor (EGF) vaccination represents a promising novel immunotherapy strategy for non-small-cell lung cancer.
- Further in-depth review of efficacy and toxicity data is warranted to establish its role in clinical practice.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
